- Home
- CHCT vs CRVS Comparison
CHCT vs CRVS Comparison
Compare CHCT & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHCT
- CRVS
- Stock Information
- Founded
- CHCT 2014
- CRVS 2014
- Country
- CHCT United States
- CRVS United States
- Employees
- CHCT 37
- CRVS N/A
- Industry
- CHCT Real Estate Investment Trusts
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- CHCT Real Estate
- CRVS Health Care
- Exchange
- CHCT Nasdaq
- CRVS Nasdaq
- Market Cap
- CHCT 559.3M
- CRVS 516.0M
- IPO Year
- CHCT 2015
- CRVS 2016
- Fundamental
- Price
- CHCT $20.18
- CRVS $5.22
- Analyst Decision
- CHCT Buy
- CRVS Strong Buy
- Analyst Count
- CHCT 4
- CRVS 5
- Target Price
- CHCT $21.25
- CRVS $12.38
- AVG Volume (30 Days)
- CHCT 266.0K
- CRVS 1.6M
- Earning Date
- CHCT 02-11-2025
- CRVS 11-12-2024
- Dividend Yield
- CHCT 9.30%
- CRVS N/A
- EPS Growth
- CHCT N/A
- CRVS N/A
- EPS
- CHCT N/A
- CRVS N/A
- Revenue
- CHCT $115,612,000.00
- CRVS N/A
- Revenue This Year
- CHCT N/A
- CRVS N/A
- Revenue Next Year
- CHCT $7.55
- CRVS N/A
- P/E Ratio
- CHCT N/A
- CRVS N/A
- Revenue Growth
- CHCT 6.00
- CRVS N/A
- 52 Week Low
- CHCT $15.06
- CRVS $1.30
- 52 Week High
- CHCT $28.10
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- CHCT 64.82
- CRVS 41.23
- Support Level
- CHCT $18.45
- CRVS $4.60
- Resistance Level
- CHCT $19.23
- CRVS $6.47
- Average True Range (ATR)
- CHCT 0.56
- CRVS 0.39
- MACD
- CHCT 0.11
- CRVS 0.06
- Stochastic Oscillator
- CHCT 97.22
- CRVS 33.16
About CHCT Community Healthcare Trust Incorporated
Community Healthcare Trust Inc is an integrated healthcare real estate company in the United States. The company owns and acquires, or finances, real estate properties that are leased to hospitals, doctors, healthcare systems or other healthcare service providers in non-urban markets. The company derives majority of its revenues from its real estate property and mortgage notes portfolio. The company's rental and mortgage interest income is recognized based on contractual arrangements with its tenants and borrowers.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).